Kristina M. Haley

Kristina M. Haley

Auto-generated profile, based on publicly available information

Kristina M. Haley

Oregon Health and Science University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2016 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
SBS. M. Baker‐Groberg
S. M. Baker‐Groberg
SLS. Lattimore
S. Lattimore
MRM. Recht
M. Recht
OMO. J. T. McCarty
O. J. T. McCarty
KHK. M. Haley
K. M. Haley
Essentials Assays are needed to aid in the diagnosis of platelet dysfunction in the neonatal population. We developed small‐volume assays to assess neonatal platelet activation and aggregation. Compared to adult platelets, neonatal platelet activation and secretion was reduced. The extent of neonatal and adult platelet adhesion and aggregate formation were similar. Summary Background Acquired and inherited bleeding disorders may present in the neonatal period with devastating lifelong effects. Diagnosing bleeding disorders in the neonatal population could aid in preventing and treating the associated complications. However, currently available platelet function testing is limited in neonates, owing to difficulties in obtaining an adequate blood volume, a lack of normal reference ranges, and an incomplete understanding of the neonatal platelet functional phenotype. Objective To develop small‐volume, whole blood platelet function assays in order to quantify and compare neonatal and adult platelet function. Methods and Results Peripheral blood was obtained from healthy, full‐term neonates at 24 h of life. Platelet activation, secretion and aggregation were measured via flow cytometry. Platelet adhesion and aggregation were assessed under static and flow conditions. As compared with adult platelets, peripheral neonatal platelet P‐selectin expression and integrin glycoprotein IIbIIIa activation were significantly reduced in response to the G‐protein‐coupled receptor (GPCR) agonists thrombin receptor activator peptide‐6 (TRAP‐6), ADP, and U46619, and the immunoreceptor tyrosine‐based activation motif (ITAM) signaling pathway agonists collagen‐related peptide (CRP) and rhodocytin. Neonatal platelet aggregation was markedly reduced in response to TRAP‐6, ADP, U46619, CRP and rhodocytin as compared with adult platelets. The extents of neonatal and adult platelet adhesion and aggregate formation under static and shear conditions on collagen and von Willebrand factor were similar. Conclusions As compared with adult platelets, we found that neonatal platelet activation and secretion were blunted in response to GPCR or ITAM agonists, whereas the extent of neonatal platelet adhesion and aggregate formation was similar to that of adult platelets.

6 June 2017 in Frontiers in Pediatrics
Verified
Journal Article
Open access
KHKristina M. Haley
Kristina M. Haley
Neonates are the pediatric population at highest risk for development of venous thromboembolism (VTE), and the incidence of VTE in the neonatal population is increasing. This is especially true in the critically ill population. Several large studies indicate that the incidence of neonatal VTE is up almost three fold in the last two decades. Central lines, fluid fluctuations, sepsis, liver dysfunction, and inflammation contribute to the risk profile for VTE development in ill neonates. In addition, the neonatal hemostatic system is different from that of older children and adults. Platelet function, pro- and anti-coagulant proteins concentrations, and fibrinolytic pathway protein concentrations are developmentally regulated and generate a hemostatic homeostasis that is unique to the neonatal time period. The clinical picture of a critically ill neonate combined with the physiologically distinct neonatal hemostatic system easily fulfills the criteria for Virchow’s Triad with venous stasis, hypercoaguability, and endothelial injury and puts the neonatal patient at risk for VTE development. The presentation of a VTE in a neonate is similar to that of older children or adults and is dependent upon location of the VTE. Ultrasound is the most common diagnostic tool employed in identifying neonatal VTE, but relatively small vessels of the neonate as well as frequent low pulse pressure can make ultrasound less reliable. The diagnosis of a thrombophilic disorder in the neonatal population is unlikely to change management or outcome, and the role of thrombophilia testing in this population requires further study. Treatment of neonatal VTE is aimed at reducing VTE associated morbidity and mortality. Recommendations for treating, though, can not be extrapolated from guidelines for older children or adults. Neonates are at risk for bleeding complications, particularly younger neonates with more fragile intracranial vessels. Developmental alterations in the coagulation proteins as well as unique pharmacokinetics must also be taken into consideration when recommending VTE treatment. In this review, epidemiology of neonatal VTE, pathophysiology of neonatal VTE with particular attention to the developmental hemostatic system, diagnostic evaluations of neonatal VTE, and treatment guidelines for neonatal VTE will be reviewed.

18 June 2014 in Pediatric Research
Verified
Journal Article
Open access
PDF file
KHKristina M. Haley
Kristina M. Haley
MRMichael Recht
Michael Recht
OMOwen J.T. McCarty
Owen J.T. McCarty
The human hemostatic system is developmentally regulated, resulting in qualitative and quantitative differences in the mediators of primary and secondary hemostasis as well as fibrinolysis in neonates and infants. Although gestational age–related differences in coagulation factor levels occur, the existence of a unique neonatal platelet phenotype remains controversial. Complicated by difficulties in obtaining adequate neonatal blood volumes with which to perform functional assays, ambiguity surrounds the characterization of neonatal platelets. Thus, much of the current knowledge of neonatal platelet function has been based on studies from cord blood samples. Studies suggest that cord blood–derived platelets, as a surrogate for neonatal platelets, are hypofunctional when compared with adult platelets. This relative platelet dysfunction, combined with a propensity toward thrombocytopenia in the neonatal intensive care unit population, creates a clinical conundrum regarding the appropriate administration of platelet transfusions. This review provides an appraisal of the distinct functional phenotype of neonatal platelets. Neonatal platelet transfusion practices and the impact of the relatively hypofunctional neonatal platelet on those practices will be considered.

1 March 2017 in Medical Clinics of North America
Verified
Journal Article
Closed access
KHKristina Haley
Kristina Haley

3 January 2020 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
ACAaron J. Cunningham
Aaron J. Cunningham
EDElizabeth Dewey
Elizabeth Dewey
SLSaunders Lin
Saunders Lin
KHKristina M. Haley
Kristina M. Haley
EBErin C. Burns
Erin C. Burns
MJMubeen A. Jafri
Mubeen A. Jafri

1 May 2020 in Journal of Women's Health
Verified
Journal Article
Closed access
KHKristina M. Haley
Kristina M. Haley
RSRobert F. Sidonio
Robert F. Sidonio
SAShirley Abraham
Shirley Abraham
DCDunlei Cheng
Dunlei Cheng
MRMichael Recht
Michael Recht
RKRoshni Kulkarni
Roshni Kulkarni
Introduction: The number of women and girls (WG) with bleeding disorders cared for at hemophilia treatment centers has increased dramatically over the last 30 years, owing to improved recognition of bleeding symptoms specific to WG. However, basic epidemiologic data of this population remain elusive. The ATHNdataset (American Thrombosis and Hemostasis Network) is a surveillance tool for people with bleeding disorders in the United States, providing demographic as well as bleeding symptom and treatment information. The aim of this study was to characterize the female cohort within the ATHNdataset. Methods: In this retrospective cohort study, the ATHNdataset was queried for demographic data, bleeding disorder diagnosis, bleeding symptoms, and treatment. Descriptive statistics were used. Results: As of December 31, 2017, 8,820 WG with a congenital bleeding disorder were enrolled in the ATHNdataset, comprising 24.5% of the entire ATHNdataset cohort (35,945). The most common reported diagnosis was von Willebrand disease (VWD), accounting for 62.9% of the population. Reproductive tract bleeding was reported in 15.8% of participants older than 15 years. Conclusions: The ATHNdataset describes the largest cohort of WG with bleeding disorders to date. VWD is the most common diagnosis in WG with bleeding disorders. Symptoms specific to WG, such as heavy menstrual bleeding, are underreported in this data set compared with other data sources. Ongoing efforts are needed to improve diagnosis, treatment, and surveillance of WG with bleeding disorders.